Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

Campese, Nicole; Palermo, Giovanni; Gamba, Claudia Del; Beatino, Maria Francesca; Galgani, Alessandro; Belli, Elisabetta; Prete, Eleonora Del; Vecchia, Alessandra Della; Vergallo, Andrea; Siciliano, Gabriele; Ceravolo, Roberto; Hampel, Harald; Baldacci, Filippo

doi:10.1080/14789450.2021.1886929

Cited by 11 publications

(7 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early prediction of the onset of AD is crucially important for timely prevention and early intervention in this disease. However, the current tools that are used for identifying AD pathology pre-mortem, including brain tau and Aβ PET imaging and CSF protein analysis, are expensive, time-consuming and invasive 24,[38][39][40][41][42][43][44][45]55,56 . Although these methods have been used to predict pathology before clinical symptoms have developed, their invasiveness and cost have limited their use to well funded research settings in academic centers.…”

Section: Discussionmentioning

confidence: 99%

“…Using our novel assay, we identified TTR, Aβ, tau231 and α-syn as constituents of the aggregates seen in ADTs exposed to sera from patients with AD and MCI. Prior studies have shown that the concentration of a single protein such as Aβ and a tau protein is increased in the CSF or blood in AD 24,[38][39][40][41][42][43][44][45]55,56 . However, it was not clear whether these proteins are present as aggregates in biofluids.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease

Cheng

Banerjee

Daiello

et al. 2021

Sci Rep

View full text Add to dashboard Cite

A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer’s disease (AD) and other proteinopathy diseases. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with impaired autophagy. We hypothesized that induced autophagy deficiency would promote accumulation of pathologic protein aggregates. Here, we describe a novel, sensitive assay that detects serum protein aggregates from patients with PE (n = 33 early onset and 33 late onset) and gestational age-matched controls (n = 77) as well as AD in both dementia and prodromal mild cognitive impairment (MCI, n = 24) stages with age-matched controls (n = 19). The assay employs exposure of genetically engineered, autophagy-deficient human trophoblasts (ADTs) to serum from patients. The aggregated protein complexes and their individual components, including transthyretin, amyloid β-42, α-synuclein, and phosphorylated tau231, can be detected and quantified by co-staining with ProteoStat, a rotor dye with affinity to aggregated proteins, and respective antibodies. Detection of protein aggregates in ADTs was not dependent on transcriptional upregulation of these biomarkers. The ROC curve analysis validated the robustness of the assay for its specificity and sensitivity (PE; AUC: 1, CI: 0.949–1.00; AD; AUC: 0.986, CI: 0.832–1.00). In conclusion, we have developed a novel, noninvasive diagnostic and predictive assay for AD, MCI and PE.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease

Cheng

Banerjee

Daiello

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Se ha hallado superposición genética, neuropatológica y clínica entre la demencia frontotemporal (DFT) algunas afasias progresivas primarias (APP), la esclerosis lateral amiotrófica (ELA) y trastornos del movimiento antes considerados parkinsonismos atípicos o parkinsonismos plus (Mark, 2001) como la degeneración corticobasal (DCB) (Rebeiz et al, 1967;Armstrong et al, 2013;Alexander et al, 2014) y la parálisis supranuclear progresiva (PSP) o enfermedad de Steele-Richardson-Olszewski (Steele et al, 1964;Boxer et al, 2017;Höglinger et al, 2017). Esto llevó a la nueva clasificación de estos cuadros como proteinopatías (Bayer, 2015;Campese et al, 2021;Chopra et al, 2022), adscribiendo los mismos a diferentes perfiles genéticos (ver Tabla 1). Todas estas patologías comparten la presentación de compromiso cognitivo, conductual y funcional, muchas veces asociado a trastornos del sistema nervioso autónomo.…”

Section: Trastornos De Conducta Y Psicosis En Neurologíaunclassified

Psicosis tardías y fenocopias

Ollari,

Deschle,

Rubiño

et al. 2023

Vertex Rev Arg Psiquiatr

View full text Add to dashboard Cite

Los síntomas psicóticos pueden manifestarse a cualquier edad, pero en las personas mayores representan un verdadero desafío diagnóstico. Pueden observarse trastornos del pensamiento, alucinaciones (usualmente visuales), trastornos del estado de ánimo con ideas delirantes, trastornos en la interacción social y ocasionalmente agresividad verbal o física (Karon & VandenBos, 1998). Desde lasprimeras descripciones de la psiquiatría clásica se ha intentado definir a las psicosis observadas en las personas mayores y determinar si se trata de síndromes “psiquiátricos” primarios o, por el contrario, si se los puede atribuir a otras patologías. Así, han surgido diferentes conceptos, como psicosis de comienzo tardío (Late Onset Psychosis) o esquizofrenia de comienzo tardío (Late-Onset Schizophrenia – LOS), psicosis de comienzo muy tardío (Very Late-Onset Psychosis)o psicosis esquizofreniforme de comienzo muy tardío (very late-onset schizophrenia-like psychosis – VLOSL), psicosis de la vida avanzada (Late-Life Psychosis), etc.

show abstract

“…Current biomarkers (Aβ, tau, and neurodegeneration) are measured in CSF or by brain neuroimaging. Specific Aβ-PET and tau-PET tracers enable the study of the misfolded and accumulated proteins (but not monomers and oligomers) in the brain in vivo [ 95 , 96 , 97 , 98 , 99 ]. In the brain, Aβ deposition may be monitored by 11 C-Pittsburgh compound B ( 11 C-PiB) or 18 F-florbetapir PET; tau deposition can be monitored using newer 18 F-based tau binding ligands; and neurodegeneration and synaptic damage can be observed via 18 F-fluorodeoxyglucose ( 18 F-FDG) PET or structural magnetic resonance imaging (MRI) data analysis [ 27 , 100 , 101 ].…”

Section: Risk Factors and Biomarkers Of Alzheimer’s Diseasementioning

confidence: 99%

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets

Fišar

2022

Biomolecules

View full text Add to dashboard Cite

Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as Alzheimer’s disease (AD). Injury to synapses and neurons and accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles are considered the main morphological and neuropathological features of AD. Age, genetic and epigenetic factors, environmental stressors, and lifestyle contribute to the risk of AD onset and progression. These risk factors are associated with structural and functional changes in the brain, leading to cognitive decline. Biomarkers of AD reflect or cause specific changes in brain function, especially changes in pathways associated with neurotransmission, neuroinflammation, bioenergetics, apoptosis, and oxidative and nitrosative stress. Even in the initial stages, AD is associated with Aβ neurotoxicity, mitochondrial dysfunction, and tau neurotoxicity. The integrative amyloid-tau-mitochondrial hypothesis assumes that the primary cause of AD is the neurotoxicity of Aβ oligomers and tau oligomers, mitochondrial dysfunction, and their mutual synergy. For the development of new efficient AD drugs, targeting the elimination of neurotoxicity, mutual potentiation of effects, and unwanted protein interactions of risk factors and biomarkers (mainly Aβ oligomers, tau oligomers, and mitochondrial dysfunction) in the early stage of the disease seems promising.

show abstract

Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

Cited by 11 publications

References 199 publications

Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease

Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease

Psicosis tardías y fenocopias

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets

Contact Info

Product

Resources

About